CART BP Sets New Benchmark in Blood Pressure Monitoring
Sky Labs has announced that its innovative CART BP, a ring-type wearable blood pressure monitor, has become the first device globally to complete comparative studies with all three major blood pressure measurement methods. This groundbreaking achievement establishes CART BP as the only cuffless device to demonstrate accuracy in studies with the auscultatory method, invasive arterial pressure measurement, and 24-hour Ambulatory Blood Pressure Monitoring (ABPM).
Comparative Studies Across All Methods
The comprehensive studies, conducted at Seoul National University Hospital, included comparisons with the traditional cuff-based auscultatory method, which uses a stethoscope for clinic-based readings, and the invasive arterial method that involves inserting a catheter into an artery. The 24-hour ABPM study is particularly noteworthy as it aligns with the European Society of Hypertension’s (ESH) 2023 guidelines, reflecting the rigorous standards for validating cuffless devices. The findings from this research were published in the Korean Circulation Journal (KCJ).
Significance of the Research
The research into CART BP’s effectiveness was also validated against invasive arterial measurements and standard stethoscopic methods, with results featured in Nature Scientific Reports and the Journal of Korean Medical Science (JKMS). This multi-method validation underscores the device’s reliability and its potential to enhance diagnostic accuracy in various settings. The studies included a diverse patient population, ensuring that CART BP’s performance is robust across different demographics and health conditions.
Innovative Features and Impact
CART BP stands out for its ability to measure blood pressure continuously, including during sleep, offering a significant advantage over traditional monitors. Its 24/7 monitoring capability provides valuable insights into blood pressure variability, which can be crucial for diagnosing conditions that fluctuate throughout the day. This continuous monitoring feature allows users to track their blood pressure in real-time via a smartphone app, making it easier to manage their health proactively. Additionally, the device is designed for comfort and convenience, seamlessly integrating into daily life without causing disruption.
Future Goals and Approvals
Sky Labs aims to leverage these successful research outcomes to secure US FDA and European CE approvals for CART BP. CEO Jack Lee expressed confidence in CART BP’s potential to revolutionise blood pressure monitoring by providing a more user-friendly and accurate alternative to existing methods. “We are excited to see CART BP prove its effectiveness against all major blood pressure measurement methods and look forward to advancing regulatory approvals this year,” Lee stated.
Contributing to Accurate Diagnoses
By enabling continuous 24-hour monitoring and overcoming traditional limitations, CART BP is poised to play a crucial role in advancing blood pressure management and diagnosis. The device’s ability to detect various forms of hypertension—such as white coat syndrome, masked hypertension, and nocturnal hypertension—is particularly valuable. These conditions can be challenging to diagnose in a clinical setting but are critical for effective treatment. The development of CART BP is expected to contribute significantly to more accurate assessments and better patient outcomes in the field of hypertension.
Enhancing Patient Engagement and Health Management
Moreover, CART BP empowers patients by providing them with actionable insights into their blood pressure patterns. This increased engagement in their own health management can lead to better adherence to treatment plans and lifestyle modifications. As the healthcare industry continues to evolve, CART BP represents a significant advancement in wearable technology and personalized health monitoring.